ARSB and mucolipidosis type II: To test this possibility, we have generated IDUA KO cells (MPS Type I model), ARSB KO cells (MPS Type VI model), GUSB KO (MPS Type VII model), and GNPTAG KO cells (Mucolipidosis Type II/ML Type II model) by genome editing, and tested the GAG core protein suppressive effect of triclabendazole on these disease model cells.